The estimated Net Worth of Kevin Krenitsky is at least 57.8 千$ dollars as of 19 May 2016. Kevin Krenitsky owns over 43,716 units of Enzo Biochem stock worth over 57,776$ and over the last 15 years Kevin sold ENZ stock worth over 0$.
Sign up
Kevin Krenitsky ENZ stock SEC Form 4 insiders trading
Kevin has made over 1 trades of the Enzo Biochem stock since 2016, according to the Form 4 filled with the SEC. Most recently Kevin bought 43,716 units of ENZ stock worth 48,525$ on 19 May 2016.
The largest trade Kevin's ever made was buying 43,716 units of Enzo Biochem stock on 19 May 2016 worth over 48,525$. On average, Kevin trades about 5,465 units every 0 days since 2009. As of 19 May 2016 Kevin still owns at least 52,050 units of Enzo Biochem stock.
You can see the complete history of Kevin Krenitsky stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Kevin Krenitsky's mailing address?
Kevin's mailing address filed with the SEC is C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG, MD, 20878.
Insiders trading at Enzo Biochem
Over the last 22 years, insiders at Enzo Biochem have traded over 2,615,763$ worth of Enzo Biochem stock and bought 1,070,494 units worth 3,103,461$ . The most active insiders traders include Bradley Louis Radoff、Management Corp Harbert Dis...、Elazar Rabbani. On average, Enzo Biochem executives and independent directors trade stock every 127 days with the average trade being worth of 59,099$. The most recent stock trade was executed by Kara Cannon on 21 February 2024, trading 10,640 units of ENZ stock currently worth 11,810$.
What does Enzo Biochem do?
enzo biochem inc is a financial services company located in 60 executive blvd, farmingdale, new york, united states.
What does Enzo Biochem's logo look like?
Complete history of Kevin Krenitsky stock trades at Opgen Inc、Enzo Biochem
Enzo Biochem executives and stock owners
Enzo Biochem executives and other stock owners filed with the SEC include:
-
Elazar Rabbani,
Chairman of the Board, Chief Executive Officer, Secretary -
Barry Weiner,
President, Treasurer -
Dr. Elazar Rabbani Ph.D.,
Co-Founder, Chairman, Chief Scientific Officer & Sec. -
Barry W. Weiner,
Founder, Treasurer & Pres -
Dieter Schapfel,
Chief Medical Director - Enzo Clinical Labs -
Kara Cannon,
Chief Commercial Officer -
Dr. Dieter Schapfel M.D.,
Chief Medical Director of Enzo Clinical Labs -
David Bench,
Chief Financial Officer, Principal Accounting Officer -
David A. Bench,
CFO & Principal Accounting Officer -
Dov Perlysky,
Lead Independent Director -
Rebecca Fischer,
Independent Director -
Ian Walters,
Independent Director -
Mary Tagliaferri,
Independent Director -
Kara Cannon,
Chief Commercial Officer -
Hamid Erfanian,
CEO & Director -
Bruce A. Dey,
VP of Sales & Marketing - Enzo Clinical Labs -
Gregory M. Bortz,
Director -
Bernard L Kasten,
Director -
David C Goldberg,
VP CorpDev Pres Enz Clin Labs -
Steven J Pully,
Director -
Bruce A. Hanna,
Director -
James Michael O'brien,
EVP of Finance -
Peter J Iv Clemens,
10% owner -
Management Corp Harbert Dis...,
-
Stanford S Warshawsky,
Director -
Fabian Blank,
Director -
Christine Fischette,
Pres., Enzo Therapeutics, Inc. -
Irwin Gerson,
Director -
John Delucca,
Director -
Stephen B H Kent,
Director -
Dean Engelhardt,
Executive Vice President -
Melvin F Lazar,
Director -
Barbara E Thalenfeld,
VP Corporate Development -
John B Sias,
Director -
Carl W Balezentis,
Pres., Enzo Life Sciences -
Kevin Krenitsky,
President, Enzo Clinical Labs -
Shahram K Rabbani,
COO, Treasurer & Secretary -
Norman E Kelker,
Senior Vice President -
Herbert B Bass,
VP of Finance -
Andrew P Whiteley,
VP BusDev-COO Enzo Lif Sci Inc -
Bradley Louis Radoff,
Director -
James G. Wolf,
-
Hamid Erfanian,
Chief Executive Officer -
Patricia Eckert,
Chief Financial Officer